Shots:

• Novartis to receive $13B (£9.2B) as total deal value from GSK. GSK to acquire 36.5% stake (63.5% already acquired in 2014) in Consumer Healthcare Joint Venture- formed in 2014 with Novartis
• The focus of the agreement is to utilize the venture for manufacturing of OTC- oral health brands- pharmaceutical and vaccines such as Sensodyne and Eno in Vemgal- Karnataka and Nashik
• Additionally- GSK plans to review Horlicks and healthcare nutrition products to support the transaction. In April 2014- GSK and Novartis signed a joint agreement to create Consumer Healthcare business focusing on Consumer Healthcare- Vaccines and Oncology products

Ref: GSK | Image: GSK